Title of article
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Author/Authors
Bonaventura Clotet، نويسنده , , Nicholas Bellos، نويسنده , , Jean-Michel Molina، نويسنده , , David Cooper Crane، نويسنده , , Jean-Christophe Goffard، نويسنده , , Adriano Lazzarin، نويسنده , , Andrej Wohrmann، نويسنده , , Christine Katlama، نويسنده , , Timothy Wilkin، نويسنده , , Richard Haubrich، نويسنده , , Calvin Cohen، نويسنده , , Charles Farthing، نويسنده , , Dushyantha Jayaweera، نويسنده , , Martin Markowitz، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
10
From page
1169
To page
1178
Abstract
Summary
Background
The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced HIV-1-infected patients. We did a pooled subgrou
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
591167
Link To Document